Alzheimer’s drug, the monoclonal antibody lecanemab, slowed decline in a phase 3 clinical trial, the company said.
Related Articles
-
The first pill for postpartum depression is finally getting to patients. Doctors say it’s working.
It was supposed to be an exciting time. The new mother had just given birth at age 42, after...
-
Measles is a ‘heat-seeking missile’ experts warn as Florida outbreak grows
The Florida measles outbreak is expanding. On Friday, health officials inBroward County confirmed a seventh case of the virus,...
-
Doctors on alert for rare blood clots linked to J&J vaccine
Doctors across the country are on high alert for rare blood clots linked to the Johnson & Johnson Covid-19...
-
The CDC has identified 19 monkeypox cases in the U.S. Here’s what we know so far.
The Centers for Disease Control and Prevention had confirmed 19 cases of monkeypox across 10 U.S. states as of...
-
As more people report Paxlovid rebounds of Covid, experts insist the cases are rare
When Dr. Anthony Fauci got Covid in June, he took Paxlovid, an antiviral drug for people with mild to...
-
Marijuana users found to have lead and another heavy metal in their blood and urine
Some marijuana users may have elevated levels of lead and cadmium — two heavy metals linked to long-term health...
-
House Oversight Committee hears emotional testimony on Black material health crisis
IE 11 is not supported. For an optimal experience visit our site on another browser. 09:32 Share this –...
-
Farmers will now get paid to test their dairy cows for bird flu
Federal authorities on Friday pledged nearly $200 million in an attempt to control the spread of bird flu on...
Recent Comments